{'fraction_non_alphanumeric': 0.02997275204359673, 'fraction_numerical': 0.02316076294277929, 'mean_word_length': 5.621621621621622, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Biologic modulation of chemotherapy in patients with hepatic colorectal metastases: The role of anti‐VEGF and anti‐EGFR antibodies

In the treatment of metastatic colorectal cancer, the subset of patients with liver‐only metastases shows the greatest promise for prolonged survival and cure. Advances in surgery and medical treatment have encouraged multimodality treatment strategies and therefore require a true multidisciplinary approach. The current standard of care includes peri‐operative chemotherapy and surgery. The new era of biologically targeted therapy requires an in‐depth look at the possible efficacy and risks of adding these agents to the treatment protocol. J. Surg. Oncol. 2010;102:937–945. © 2010 Wiley‐Liss, Inc.